Additional cytokine blocking agents targeting IL-6 (a factor during effector Th17 T-cell differentiation) or the IL-23/IL-17 axis have been considered for SAPHO because of clinical overlaps with psoriasis and spondylarthritis.23 24 54 Nine patients were treated across three studies from China, France and Australia. The gene discussed is IL6; the disease is psoriasis.